Company

Fully Funded Assets

XOMA currently has more than 20 partnered and fully-funded programs with the potential to drive milestone and royalty payments.

Over 20 of the licenses in our portfolio are to antibodies that were discovered internally.  The development and commercialization rights to these assets were acquired by pharmaceutical and biotechnology companies, and they fund 100% of the development and commercialization investment.

 

Transformational License Agreements with Novartis
XOMA has licensed the global commercial rights to gevokizumab, a novel anti-IL-1 beta allosteric monoclonal antibody, to Novartis. In a separate agreement, XOMA has granted Novartis a license to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment of cardiovascular disease.

Major drug study opens up vast new opportunities in combating heart disease
(Washington Post)